Ask AI

Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches

Gain in-depth knowledge on the medical need and rationale for using PARP inhibitor–based treatment in patients with metastatic castration-resistant prostate cancer, including best practices in testing to inform treatment selection, recent guideline updates, and toxicity management, through an on-demand webcast with accompanying slides and an expert-written ClinicalThought.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Johnson & Johnson and Pfizer Inc.

Johnson & Johnson

Pfizer, Inc.